Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice

International Journal of Infectious Diseases

Volumn 29, Issue , 2014, Pages 31-36

  Wang, Ying ^a   Chen, Kun ^a   Wu, Zhiyuan ^a   Liu, Yuetao ^b   Liu, Shangmei ^a   Zou, Zhongmei ^b   Chen, Shu Hsia ^c   Qu, Chunfeng ^a  

^a CANCER HOSPITAL   (China)

^b INSTITUTE OF MEDICINAL PLANT DEVELOPMENT   (China)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antigen specific Th1 responses; Chronic hepatitis B virus infection; Immune tolerant state; Toll like receptor 7 8 agonists

Indexed keywords

ALANINE AMINOTRANSFERASE; CL 097; GAMMA INTERFERON; HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; CL097 COMPOUND; HEPATITIS B ANTIBODY; IMIDAZOLE DERIVATIVE; MEMBRANE PROTEIN; QUINOLINE DERIVATIVE; TLR7 PROTEIN, MOUSE; TLR8 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; C57BL 6 MOUSE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG CONJUGATION; HEPATITIS B VIRUS; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; QUADRUPOLE MASS SPECTROMETRY; REGULATORY T LYMPHOCYTE; SPLEEN CELL; TIME OF FLIGHT MASS SPECTROMETRY; TRANSGENIC MOUSE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VACCINATION; AGONISTS; ANIMAL; BLOOD; C57BL MOUSE; DRUG EFFECTS; HEPATITIS B; IMMUNOLOGY; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; IMIDAZOLES; IMMUNE TOLERANCE; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; QUINOLINES; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8; VACCINATION;

EID: 84910040995     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2014.07.015     Document Type: Article

References (33)

1. Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011, 34:637-650.
2. Cheong C., Matos I., Choi J.H., Dandamudi D.B., Shrestha E., Longhi M.P., et al. Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. Cell 2010, 143:416-429.
3. Dubensky T.W., Reed S.G. Adjuvants for cancer vaccines. Semin Immunol 2010, 22:155-161.
4. Mbow M.L., De Gregorio E., Valiante N.M., Rappuoli R. New adjuvants for human vaccines. Curr Opin Immunol 2010, 22:411-416.
5. Ilan Y., Nagler A., Adler R., Naparstek E., Or R., Slavin S., et al. Adoptive transfer of immunity to hepatitis B virus after T cell-depleted allogeneic bone marrow transplantation. Hepatology 1993, 18:246-252.
6. Lau G.K., Suri D., Liang R., Rigopoulou E.I., Thomas M.G., Mullerova I., et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 2002, 122:614-624.
7. Mancini M., Hadchouel M., Davis H.L., Whalen R.G., Tiollais P., Michel M.L. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc Natl Acad Sci U S A 1996, 93:12496-12501.
8. Hong Y., Peng Y., Mi M., Xiao H., Munn D.H., Wang G.Q., et al. Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice. Vaccine 2011, 29:3909-3916.
9. Niedre-Otomere B., Bogdanova A., Skrastina D., Zajakina A., Bruvere R., Ose V., et al. Recombinant Semliki Forest virus vectors encoding hepatitis B virus small surface and pre-S1 antigens induce broadly reactive neutralizing antibodies. J Viral Hepat 2012, 19:664-673.
10. Akbar S.M., Furukawa S., Horiike N., Abe M., Hiasa Y., Onji M. Safety and immunogenicity of hepatitis B surface antigen-pulsed dendritic cells in patients with chronic hepatitis B. J Viral Hepat 2011, 18:408-414.
11. Michel M.L., Deng Q., Mancini-Bourgine M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol 2011, 54:1286-1296.
12. Xu D.Z., Wang X.Y., Shen X.L., Gong G.Z., Ren H., Guo L.M., et al. Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol 2013, 59:450-456.
13. Maini M.K., Boni C., Lee C.K., Larrubia J.R., Reignat S., Ogg G.S., et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000, 191:1269-1280.
14. Yang P.L., Althage A., Chung J., Maier H., Wieland S., Isogawa M., et al. Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A 2010, 107:798-802.
15. Qu C., Nguyen V., Merad M., Randolph G. MHC class I/peptide transfer between dendritic cells overcomes poor cross-presentation by monocyte-derived APCs that engulf dying cells. J Immunol 2009, 182:3650-3659.
16. Du J., Wu Z., Ren S., Wei Y., Gao M., Randolph G.J., et al. TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity. Vaccine 2010, 28:6273-6281.
17. Wille-Reece U., Flynn B.J., Lore K., Koup R.A., Kedl R.M., Mattapallil J.J., et al. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci U S A 2005, 102:15190-15194.
18. Wille-Reece U., Flynn B.J., Lore K., Koup R.A., Miles A.P., Saul A., et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 2006, 203:1249-1258.
19. Levy O., Suter E.E., Miller R.L., Wessels M.R. Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. Blood 2006, 108:1284-1290.
20. Kastenmuller K., Wille-Reece U., Lindsay R.W., Trager L.R., Darrah P.A., Flynn B.J., et al. Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. J Clin Invest 2011, 121:1782-1796.
21. Liu G., Xiong Y., Wang H., Jia Y., Zhou J., Pan F., et al. Establishment of high level expression HBV transgenic BALB/c mice and its genetic and expressive stability. Chinese Journal of Veterinary Science 2003, 23:580-582.
22. Chisari F.V., Pinkert C.A., Milich D.R., Filippi P., McLachlan A., Palmiter R.D., et al. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science 1985, 230:1157-1160.
23. Shen M., Wang S., Ge G., Xing Y., Ma X., Huang Z., et al. Profiles of B and T cell immune responses elicited by different forms of the hepatitis B virus surface antigen. Vaccine 2010, 28:7288-7296.
24. Hsieh C.S., Lee H.M., Lio C.W. Selection of regulatory T cells in the thymus. Nat Rev Immunol 2012, 12:157-167.
25. Sharma M.D., Hou D.Y., Baban B., Koni P.A., He Y., Chandler P.R., et al. Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity 2010, 33:942-954.
26. Edmunds W.J., Medley G.F., Nokes D.J., Hall A.J., Whittle H.C. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci 1993, 253:197-201.
27. Chisari F.V., Isogawa M., Wieland S.F. Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) 2010, 58:258-266.
28. Wilson N.S., Behrens G.M., Lundie R.J., Smith C.M., Waithman J., Young L., et al. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat Immunol 2006, 7:165-172.
29. Qu C., Brinck-Jensen N.S., Zang M., Chen K. Monocyte-derived dendritic cells: targets as potent antigen-presenting cells for the design of vaccines against infectious diseases. Int J Infect Dis 2014, 19:1-5.
30. Blasius A.L., Beutler B. Intracellular toll-like receptors. Immunity 2010, 32:305-315.
31. Jurk M., Heil F., Vollmer J., Schetter C., Krieg A.M., Wagner H., et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002, 3:499.
32. Spranger S., Javorovic M., Burdek M., Wilde S., Mosetter B., Tippmer S., et al. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol 2010, 185:738-747.
33. Hsu Y.S., Chien R.N., Yeh C.T., Sheen I.S., Chiou H.Y., Chu C.M., et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002, 35:1522-1527.